What is iBeat?
iBeat operates at the intersection of consumer electronics and life-saving medical technology. Its flagship product, the iBeat Heart Watch, serves as a continuous, 24-7 cardiac monitoring solution designed to provide real-time alerts to users, their families, and emergency responders during critical health events. By positioning itself as a proactive health companion, iBeat addresses the growing demand for accessible, high-fidelity biometric data. While currently marketed as a consumer wearable, the company is actively pursuing FDA clearance to transition its technology into a formal medical device, a move that would significantly expand its addressable market and solidify its role in the digital health ecosystem.
How much funding has iBeat raised?
iBeat has raised a total of $12.7M across 3 funding rounds:
Angel/Seed
$10M
Other Financing Round
$2.5M
Debt
$150K
Angel/Seed (2018): $10M with participation from City Light Capital, 8VC, Subtraction Capital, Kairos, Plug and Play Ventures, Maveron, and ChinaRock Capital Management
Other Financing Round (2018): $2.5M led by Transamerica Ventures and Scor
Debt (2020): $150K supported by PPP
Key Investors in iBeat
City Light Capital
A venture capital firm focused on double bottom line investing, prioritizing both financial returns and positive societal impact in sectors like safety, security, and healthcare.
8VC
A prominent technology investment firm that manages significant committed capital, specializing in smart enterprise platforms across healthcare, financial services, and Bio-IT.
Maveron
A consumer-focused venture capital firm that partners with innovative entrepreneurs to disrupt traditional industries through sustainable growth and human-centric design.
What's next for iBeat?
The recent capital injection is expected to accelerate iBeat's regulatory roadmap and operational scaling. As the company moves toward potential FDA approval, the focus will likely shift toward deepening its integration with healthcare providers and insurance networks. By leveraging its existing enterprise-level backing, iBeat is well-positioned to refine its proprietary algorithms and expand its distribution channels. The strategic priority remains the transformation of the Heart Watch from a wellness accessory into a clinically validated tool, thereby creating a competitive moat in the rapidly evolving remote patient monitoring and digital health landscape.
See full iBeat company page
